Category: 74904-29-3

On January 10, 2013, Frackenpohl, Jens; Zeiss, Hans-Joachim; Heinemann, Ines; Willms, Lothar; Mueller, Thomas; Busch, Marco; Von Koskull-Doering, Pascal; Rosinger, Christopher Hugh; Dittgen, Jan; Hills, Martin Jeffrey published a patent.SDS of cas: 74904-29-3 The title of the patent was Use of substituted isoquinolinones, isoquinolinediones, isoquinolinetriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants and their preparation. And the patent contained the following:

The invention relates to the use of substituted isoquinolinones, isoquinolinediones, isoquinolinetriones and dihydroisoquinolinones of formula I or in each case salts thereof, for enhancing stress tolerance in plants against abiotic stress, for boosting plant growth and/or for increasing plant yield, and to special methods for producing the aforementioned compounds Compounds of formula I wherein Q is (un)substituted ethylene, (un)substituted ethenylene, (un)substituted oxoethylene, etc.; W is O and S; R1, R2, R3 and R4 are independently H, NO2, amino, OH, halo, etc.; R5 is H, OH, alkyl, cycloalkyl, etc.; and their salts are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their ability to protect against abiotic stress in plants (some data given). The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).SDS of cas: 74904-29-3

The Article related to isoquinolinone isoquinolinedione isoquinolinetrione preparation protection abiotic stress plant, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.SDS of cas: 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Sall, Daniel J.; Grunewald, Gary L. published an article in 1987, the title of the article was Inhibition of phenylethanolamine N-methyltransferase (PNMT) by aromatic hydroxy-substituted 1,2,3,4-tetrahydroisoquinolines. Further studies on the hydrophilic pocket of the aromatic ring binding region of the active site.Related Products of 74904-29-3 And the article contains the following content:

In a study directed toward characterizing the hydrophilic pocket within the aromatic ring binding region of the active site of phenylethanolamine N-methyltransferase (PNMT), 5-, 6-, 7-, and 8-hydroxy-1,2,3,4-tetrahydroisoquinoline were prepared and evaluated as substrates and inhibitors of PNMT. Thus, 2-MeOC6H4CH2CH2NHCO2Me was cyclized by polyphosphoric acid to give 8-methoxy-3,4-dihydroisoquinolin-1-one, which was reduced followed by demethylation to give 8-hydroxy-1,2,3,4-tetrahydroisoquinoline. In order to discern the necessity of an acidic hydrogen for interaction at this pocket the corresponding Me ethers were also evaluated. The enhanced affinity of 7-hydroxy-1,2,3,4-tetrahydroisoquinoline vs. tetrahydroisoquinoline itself indicates that a hydrophilic pocket exists off of carbon C7 in bound tetrahydroisoquinolines. The Me ethers of 5-, 6-, 7-, and 8-hydroxy-exo-2-aminobenzonorbornene and of 5- and 6-hydroxy-anti-9-aminobenzonorbornene were also evaluated for their activity as substrates and inhibitors for PNMT. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Related Products of 74904-29-3

The Article related to isoquinolinol tetrahydro preparation pnmt inhibition, phenylethanolamine methyltransferase inhibition, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Related Products of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On November 2, 2000, Mewshaw, Richard Eric; Meagher, Kristin Lynne published a patent.Computed Properties of 74904-29-3 The title of the patent was Preparation of tetrahydroisoquinolinylindole derivatives for the treatment of depression. And the patent contained the following:

The title compounds I [R1-R4 = H, halo, alkoxy, carboxamide; R5 = H, halo, CF3, CN, carbamide, alkoxy; X = (CH2)n, 4-6 membered carbocyclic ring, wherein n is an integer of 2 to 4], useful for the treatment of depression, were prepared E.g., 3-[(1,4-cis)-4-(7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)cyclohexyl]-1H-indole-5-carbonitrile was prepared by reaction of 7-methoxy-1,2,3,4-tetrahydroisoquinoline (preparation given) with 4-(5-cyano-1H-3-indolyl)cyclohexanone in presence of sodium triacetoxyborohydride and acetic acid in CH2Cl2. I are active towards 5HT1A receptors and generally elevate serotonin levels by inhibiting 5-HT transport. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Computed Properties of 74904-29-3

The Article related to isoquinolinylindole preparation depression treatment, indole isoquinolinyl preparation depression treatment, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Computed Properties of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 28, 2005, Taveras, Arthur G.; Zheng, Junying; Biju, Purakkattle J.; Yu, Younong; Chao, Jianhua; Fine, Jay; Lundell, Daniel; Priestley, Tony; Reggiani, Angelo; Merritt, J. Robert; Baldwin, John J.; Lai, Gaifa; Wu, Minglang published a patent.Electric Literature of 74904-29-3 The title of the patent was Preparation of isothiazole dioxides as CXC- and CC-chemokine receptor ligands. And the patent contained the following:

Disclosed are novel compounds I [D, E = N, CR50; provided that D and E are not the same (one is N and the other is CR50); R50 = H, CF3, CN, etc.; A = (hetero)aryl, (hetero)arylalkyl; B = (hetero)aryl] and the pharmaceutically acceptable salts and solvates thereof. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenesis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound I. Although the methods of preparation are not claimed, hundreds of example preparations and/or characterization data are included. For example, II was prepared in 68% yield from the isothiazoledioxide III and the amine IV.pTSA (preparation of reactants given). Antagonist activities of some examples of I towards CXCR1, CXCR2 and CCR7 are given. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Electric Literature of 74904-29-3

The Article related to isothiazole dioxide preparation chemokine receptor antagonist cxcr1 cxcr2 ccr7 and other aspects.Electric Literature of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On October 22, 2015, Wu, Frank published a patent.Synthetic Route of 74904-29-3 The title of the patent was Preparation of tyrosine kinase inhibitors. And the patent contained the following:

The present invention relates to tyrosine kinase inhibitors I [wherein Z1 and Z2 = independently N or (un)substituted CH; with the proviso that at least one of Z1 and Z2 is N; X = absence, O, S, (un)substituted CH or NH; Y = O, S, (un)substituted CH or NH; A = (un)substituted aryl, heteroaryl, heterocyclyl, or cycloalkyl; B and C = independently absence, (un)substituted ring or fused ring], pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof. The compounds of the present invention can be used as tyrosine kinase inhibitors, or used to reduce or inhibit the activity of EGFR or mutants thereof (for example, EGFR mutants containing T790M mutation) in cells, or used to treat and/or prevent diseases (for example, cancer) related to overactivity of EGFR, especially drug-resistant diseases (for example, cancer) caused by mutation of EGFR (for example, T790M mutation of EGFR). For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 5.7 nM against EGFR T790. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Synthetic Route of 74904-29-3

The Article related to preparation tyrosine kinase inhibitor treatment cancer egfr human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Synthetic Route of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On April 23, 2019, Shen, Jianhua; Leng, Ying; Chen, Tingting; Wang, Kai; Ning, Mengmeng published a patent.SDS of cas: 74904-29-3 The title of the patent was Preparation of amide compounds as GPR40 agonists. And the patent contained the following:

The title amide compound is shown in formula I, wherein, A is 5-7-membered heteroaryl or 6-10-membered aryl; M is O, S or N-alkyl; R1 is H or halogen; R2 is hydroxypropyl, cyclopropyl or propynyl; R3 is H, alkyl, alkoxy or halogen; R4 and R5 are independently selected from H, indanyl, alkyl, 5-7-membered heterocyclic group, etc. The inventive amide compound is capable of regulating GPR40 activity, and can be applied in treating GPR40 activity-related diseases, such as diabetes and metabolic syndrome. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).SDS of cas: 74904-29-3

The Article related to amide preparation gpr40 agonist, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.SDS of cas: 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On June 23, 2021, Fang, Yuying; Chen, Xiucai; Tan, Qingyun; Zhou, Huihao; Xu, Jun; Gu, Qiong published an article.Name: 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one The title of the article was Inhibiting Ferroptosis through Disrupting the NCOA4-FTH1 Interaction: A New Mechanism of Action. And the article contained the following:

Ferroptosis is an iron-dependent form of oxidative cell death, and the inhibition of ferroptosis is a promising strategy with which to prevent and treat neurol. diseases. Herein we report a new ferroptosis inhibitor 9a(I) with a novel mechanism of action. It is demonstrated that nuclear receptor coactivator 4 (NCOA4), a cargo receptor for ferritinophagy, is the target of 9a. Compound 9a blocks ferroptosis by reducing the amount of bioavailable intracellular ferrous iron through disrupting the NCOA4-FTH1 protein-protein interaction. Further studies indicate that 9a directly binds to recombinant protein NCOA4383-522 and effectively blocks the NCOA4383-522-FTH1 interaction. In a rat model of ischemic stroke, 9a significantly ameliorates the ischemic-refusion injury. With the first ligand 9a, this work reveals that NCOA4 is a promising drug target. Addnl., 9a is the first NCOA4-FTH1 interaction inhibitor. This work paves a new road to the development of ferroptosis inhibitors against neurol. diseases. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Name: 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

The Article related to neurol diseases ferroptosis inhibitor ncoa4 fth1 ppi iron ferritin, Pharmacology: Effects Of Nervous System- and Behavior-Affecting Drugs and Neuromuscular Agents and other aspects.Name: 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On June 11, 2021, Gu, Qiong; Xu, Jun; Fang, Yuying published a patent.Electric Literature of 74904-29-3 The title of the patent was Preparation of benzimidazole compounds for ferroptosis inhibitors. And the patent contained the following:

The present invention relates to preparation of (aryl)benzimidazole compounds for ferroptosis inhibitors. In particular, I and II [wherein, R1 is 4-methylpiperazin-1-yl, 4-methyl-1-piperidyl, 1-piperidyl, morpholino; R2 is morpholino, 1,3-benzodioxol-5-yl, 4-pyrimidin-2-ylpiperazin-1-yl, etc.; R is halogen, Me, alkoxy, alkynyloxy or hydroxy; X is C or N] were prepared The benzimidazole compound provided by the invention has better ferroptosis inhibiting activity by introducing a lipophilic group at the R1 position and introducing a specific group at the R2 position, the compound can be used as a lead compound for preventing and treating nervous system diseases such as stroke. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Electric Literature of 74904-29-3

The Article related to benzimidazole compound preparation ferroptosis inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Electric Literature of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On April 22, 2004, Taveras, Arthur G.; Chao, Jianhua; Biju, Purakkattle J.; Yu, Younong; Fine, Jay S.; Hipkin, William; Aki, Cynthia J.; Merritt, J. Robert; Li, Ge; Baldwin, John J.; Lai, Gaifa; Wu, Minglang; Hecker, Evan A. published a patent.Computed Properties of 74904-29-3 The title of the patent was Preparation of diaminothiadiazole dioxides and monoxides as CXC- and CC-chemokine receptor ligands. And the patent contained the following:

Disclosed are diaminothiadiazole mono- and dioxides (shown as I; e.g. II) and the pharmaceutically acceptable salts and solvates thereof. Examples of substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino; examples of substituent B include aryl and heteroaryl; g = 1, 2. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenesis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using I. Although the methods of preparation are not claimed, hundreds of example preparations and/or characterization data are included. For example, II was prepared in 31% yield from the 4-methoxy analog and isopropylamine in the presence of DIEA in MeOH; the 4-methoxy analog was prepared from the dimethoxy analog and N,N-dimethyl-3-amino-2-hydroxybenzamide in 99% crude yield. Antagonist activities of some examples of I towards CXCR1, CXCR2 and CCR7 are given. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Computed Properties of 74904-29-3

The Article related to aminothiadiazole oxide dioxide preparation chemokine receptor antagonist, thiadiazole diamino oxide dioxide preparation chemokine receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Computed Properties of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 21, 2005, Biju, Purakkattle J.; Taveras, Arthur G.; Yu, Younong; Zheng, Junying; Chao, Jianhua; Aki, Cynthia J.; Fine, Jay; Lundell, Daniel; Priestley, Tony; Reggiani, Angelo; Merritt, J. Robert; Baldwin, John J. published a patent.Formula: C10H11NO2 The title of the patent was Preparation of diaminothiadiazoles as CXC- and CC-chemokine receptor ligands. And the patent contained the following:

Disclosed are diaminothiadiazoles I [A = (hetero)aryl, (hetero)arylmethyl (substituted at CH2), etc.; B = (hetero)aryl] and the pharmaceutically acceptable salts and solvates thereof. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenesis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using I. Although the methods of preparation are not claimed, hundreds of example preparations and/or characterization data are included. For example, II was prepared in 43% yield from its monooxide III (preparation given). Antagonist activities of some examples of I towards CXCR1, CXCR2 and CCR7 are given. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Formula: C10H11NO2

The Article related to aminothiadiazole preparation chemokine receptor antagonist cxcr1 cxcr2 ccr7, thiadiazole diamino preparation chemokine receptor antagonist cxcr1 cxcr2 ccr7, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Formula: C10H11NO2

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem